Nabarun Dasgupta
Cited by
Cited by
Opioid crisis: no easy fix to its social and economic determinants
N Dasgupta, L Beletsky, D Ciccarone
American journal of public health 108 (2), 182-186, 2018
Cohort study of the impact of high-dose opioid analgesics on overdose mortality
N Dasgupta, MJ Funk, S Proescholdbell, A Hirsch, KM Ribisl, S Marshall
Pain medicine 17 (1), 85-98, 2016
An analysis of the root causes for opioid-related overdose deaths in the United States
LR Webster, S Cochella, N Dasgupta, KL Fakata, PG Fine, SM Fishman, ...
Pain Medicine 12 (suppl_2), S26-S35, 2011
Digital drug safety surveillance: monitoring pharmaceutical products in twitter
CC Freifeld, JS Brownstein, CM Menone, W Bao, R Filice, T Kass-Hout, ...
Drug safety 37, 343-350, 2014
Project Lazarus: community-based overdose prevention in rural North Carolina
S Albert, FW Brason, CK Sanford, N Dasgupta, J Graham, B Lovette
Pain medicine 12 (suppl_2), S77-S85, 2011
Differential prescribing of opioid analgesics according to physician specialty for Medicaid patients with chronic noncancer pain diagnoses
C Ringwalt, H Gugelmann, M Garrettson, N Dasgupta, AE Chung, ...
Pain Research and Management 19 (4), 179-185, 2014
Association between non-medical and prescriptive usage of opioids
N Dasgupta, ED Kramer, MA Zalman, S Carino Jr, MY Smith, JD Haddox, ...
Drug and alcohol dependence 82 (2), 135-142, 2006
Illicit use of opioids: Is OxyContin® a “gateway drug”?
LE Grau, N Dasgupta, LE Grau, N Dasgupta, AP Harvey, LE Grau, ...
American Journal on Addictions 16 (3), 166-173, 2007
Evaluation of Facebook and Twitter monitoring to detect safety signals for medical products: an analysis of recent FDA safety alerts
CE Pierce, K Bouri, C Pamer, S Proestel, HW Rodriguez, H Van Le, ...
Drug safety 40, 317-331, 2017
Public attitudes toward COVID-19 vaccination: The role of vaccine attributes, incentives, and misinformation
S Kreps, N Dasgupta, JS Brownstein, Y Hswen, DL Kriner
npj Vaccines 6 (1), 73, 2021
Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19
MC Figgatt, Z Salazar, E Day, L Vincent, N Dasgupta
Journal of Substance Abuse Treatment 123, 108276, 2021
Social media listening for routine post-marketing safety surveillance
GE Powell, HA Seifert, T Reblin, PJ Burstein, J Blowers, JA Menius, ...
Drug safety 39, 443-454, 2016
Observed transition from opioid analgesic deaths toward heroin
N Dasgupta, K Creppage, A Austin, C Ringwalt, C Sanford, ...
Drug and alcohol dependence 145, 238-241, 2014
Crowdsourcing black market prices for prescription opioids
N Dasgupta, C Freifeld, JS Brownstein, CM Menone, HL Surratt, ...
Journal of Medical Internet Research 15 (8), e2810, 2013
Breaking the news or fueling the epidemic? Temporal association between news media report volume and opioid-related mortality
N Dasgupta, KD Mandl, JS Brownstein
PloS one 4 (11), e7758, 2009
Recommendations for the use of social media in pharmacovigilance: lessons from IMI WEB-RADR
J van Stekelenborg, J Ellenius, S Maskell, T Bergvall, O Caster, ...
Drug Safety 42, 1393-1407, 2019
Post-marketing surveillance of methadone and buprenorphine in the United States
N Dasgupta, EJ Bailey, T Cicero, J Inciardi, M Parrino, A Rosenblum, ...
Pain Medicine 11 (7), 1078-1091, 2010
Ethics in a pandemic: a survey of the state pandemic influenza plans
JC Thomas, N Dasgupta, A Martinot
American Journal of Public Health 97 (Supplement_1), S26-S31, 2007
Comparative rates of mortality and serious adverse effects among commonly prescribed opioid analgesics
DL Murphy, JA Lebin, SG Severtson, HA Olsen, N Dasgupta, RC Dart
Drug safety 41, 787-795, 2018
Evolution and convergence of state laws governing controlled substance prescription monitoring programs, 1998-2011
CS Davis, M Pierce, N Dasgupta
American journal of public health 104 (8), 1389-1395, 2014
The system can't perform the operation now. Try again later.
Articles 1–20